- Continuous acoramidis reduced all-cause mortality by 45% (HR 0.55) and cardiovascular mortality by 49% through 54 months.
- First cardiovascular hospitalization risk was reduced (HR 0.53), with consistent benefit across prespecified subgroups.
- NT-proBNP stabilization and sustained increases in serum TTR suggest meaningful disease modification.
- Functional capacity and health status declined more slowly with early therapy; delayed initiation still provided benefit but to a lesser degree.
- Findings support early diagnosis and prompt initiation of acoramidis for optimal long-term outcomes in ATTR-CM.
From the Journals
Conference News
American College of Cardiology's 75th Annual Scientific Session & Expo
Acoramidis Linked to Lower Mortality Through 54 Months
Conexiant
April 3, 2026
